Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

Delayed Quote. Delayed  - 09/30 04:55:02 pm
86.97 USD   +2.32%
09/29 VERTEX PHARMACE : VRTX): Get In While Markets Look The Other Way
09/28 VERTEX PHARMACE : U.S. Food and Drug Administration Approves ORKAMBI..
09/22 NASDAQ 100 MOVE : Bmrn, bbby
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/26/2016 09/27/2016 09/28/2016 09/29/2016 09/30/2016 Date
88.29(c) 89.12(c) 88.84(c) 85(c) 86.97 Last
1 608 129 1 520 320 1 715 021 2 381 055 684 487 Volume
-2.58% +0.94% -0.31% -4.32% +2.32% Change
More quotes
Financials ($)
Sales 2016 1 737 M
EBIT 2016 262 M
Net income 2016 -95,2 M
Finance 2016 330 M
Yield 2016 -
Sales 2017 2 395 M
EBIT 2017 790 M
Net income 2017 482 M
Finance 2017 1 273 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 50,24
EV / Sales2016 11,9x
EV / Sales2017 8,26x
Capitalization 21 061 M
More Financials
Company
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases.It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS INC
09/29 VERTEX PHARMACEUTICALS INCORPORATED : VRTX): Get In While Markets Look The Othe..
09/28 VERTEX PHARMACEUTICALS INCORPORATED : U.S. Food and Drug Administration Approves..
09/22 NASDAQ 100 MOVERS : Bmrn, bbby
09/20 New Crystallization Development Methods Revealed in On-Demand Webinars from M..
09/19 New Crystallization Development Methods Revealed in On-Demand Webinars from M..
09/16 NASDAQ 100 MOVERS : Expe, wdc
09/15 VERTEX PHARMACEUTICALS INCORPORATED : Investigators at Vertex Pharmaceuticals In..
09/15 VERTEX PHARMACEUTICALS INCORPORATED : Researchers from Vertex Pharmaceuticals In..
09/15 VERTEX PHARMACEUTICALS INCORPORATED : Patent Issued for Solid Forms of 3-(6-(1-(..
09/15 VERTEX PHARMACEUTICALS INCORPORATED : to Present at Upcoming Investor Conference..
More news
Sector news : Bio Therapeutic Drugs
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/28 FDA approves expanded use of Vertex's CF drug Orkambi; 2016 revenue guidance ..
09/22 Biotech ETF IBB Could Get A Boost From A Potential Gilead Merger Or Acquisiti..
09/19 Sarepta to charge $300K for yearly course of Exondys 51
09/16 Healthcare ratings roundup - new coverage
09/15 Will The FDA Approve A Label Expansion For Vertex's Blockbuster Cystic Fibros..
Advertisement
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 109 $
Spread / Average Target 28%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Simon Bedson SVP & GM-International Commercial Operations
Ian F. Smith Chief Financial Officer & Executive Vice President
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..-32.45%21 061
AMGEN, INC.1.92%123 816
GILEAD SCIENCES, INC.-23.06%102 749
CELGENE CORPORATION-14.19%79 659
REGENERON PHARMACEUTIC..-25.15%42 787
ACTELION LTD21.70%18 780
More Results